RTsafe participated in the European Healthcare Startup Investment Mission to the US03April 2017
We are pleased to announce that RTsafe is one of the thirteen European high-growth startup companies selected for the European Healthcare Startup Investment Mission to the US organized under the aegis of the U.S. Department of Commerce. During this five day program, we traveled to Pittsburgh, Cleveland and Austin, three major American healthcare hubs, and met professionals and specialists from the Academic, Business and Healthcare Industry.
Our visit gave us the opportunity to network with key players and successful organizations, as well as to investigate the prospects of collaboration on the occasion of our imminent establishment in the US. We are really honored to have participated in this mission that allowed us not only to identify a broad range of business prospects, but to achieve a deeper understanding of the US market too.
Housed within the U.S. Department of Commerce, SelectUSA promotes and facilitates business investment into the United States by coordinating related federal government agencies to serve as a single point of contact for investors. SelectUSA assists U.S. economic development organizations to compete globally for investment by providing information, a platform for international marketing, and high-level advocacy. SelectUSA also helps investors find the information they need to make decisions; connect to the right people at the local level; navigate the federal regulatory system; and find solutions to issues related to the federal government. For more information, visit selectusa.
RTsafe’s mission is to increase both accuracy and safety in radiotherapy for cancer and other medical conditions. To meet this challenge, RTsafe combines proven expertise in medical physics with highly accurate 3-D printing technology to create patient-specific pre-treatment dosimetry phantoms. This innovative approach to quality assurance can upgrade the planning of precise treatment for medical professionals as well as the products of radiotherapy technology innovators.